A Novel Pyroptosis Scoring Model Was Associated with the Prognosis and Immune Microenvironment of Esophageal Squamous Cell Carcinoma

Overview

Journal Front Genet

Date 2023 Jan 23

PMID 36685978

Authors

Zhan-Fei Zhang

Affiliations

Soon will be listed here.

Abstract

The phenotype of pyroptosis has been extensively studied in a variety of tumors, but the relationship between pyroptosis and esophageal squamous cell carcinoma (ESCC) remains unclear. Here, 22 pyroptosis genes were downloaded from the website of Gene Set Enrichment Analysis (GSEA), 79 esophageal squamous cell carcinoma samples and GSE53625 containing 179 pairs of esophageal squamous cell carcinoma samples were collected from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), respectively. Then, pyroptosis subtypes of esophageal squamous cell carcinoma were obtained by cluster analysis according to the expression difference of pyroptosis genes, and a pyroptosis scoring model was constructed by the pyroptosis-related genes screened from different pyroptosis subtypes. Time-dependent receiver operator characteristic (timeROC) curves and the area under the curve (AUC) values were used to evaluate the prognostic predictive accuracy of the pyroptosis scoring model. Kaplan-Meier method with log-rank test were conducted to analyze the impact of the pyroptosis scoring model on overall survival (OS) of patients with esophageal squamous cell carcinoma. Nomogram models and calibration curves were used to further confirm the effect of the pyroptosis scoring model on prognosis. Meanwhile, CIBERSORTx and ESTIMATE algorithm were applied to calculate the influence of the pyroptosis scoring model on esophageal squamous cell carcinoma immune microenvironment. Our findings revealed that the pyroptosis scoring model established by the pyroptosis-related genes was associated with the prognosis and immune microenvironment of esophageal squamous cell carcinoma, which can be used as a biomarker to predict the prognosis and act as a potential target for the treatment of esophageal squamous cell carcinoma.

Citing Articles

A nicotinamide metabolism-related gene signature for predicting immunotherapy response and prognosis in lung adenocarcinoma patients.

Wang M, Li W, Zhou F, Wang Z, Jia X, Han X PeerJ. 2025; 13:e18991.

PMID: 40034678 PMC: 11874940. DOI: 10.7717/peerj.18991.

Construction of a novel pyrotosis-related prognostic model of esophageal square cell carcinoma and determination of the anti-tumor effect of WFDC12.

Zhuang Y, Wang L, Ji C, Sun Y, Shao F Funct Integr Genomics. 2023; 23(2):177.

PMID: 37225895 DOI: 10.1007/s10142-023-01103-2.

References

Lagergren J, Smyth E, Cunningham D, Lagergren P . Oesophageal cancer. Lancet. 2017; 390(10110):2383-2396. DOI: 10.1016/S0140-6736(17)31462-9. View

Li G, He R, Liu J, He J, Fu Z, Yang L . Prognostic signature of esophageal adenocarcinoma based on pyroptosis-related genes. BMC Med Genomics. 2022; 15(1):50. PMC: 8900411. DOI: 10.1186/s12920-022-01196-x. View

Wilkerson M, Hayes D . ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-3. PMC: 2881355. DOI: 10.1093/bioinformatics/btq170. View

Li L, Jiang M, Qi L, Wu Y, Song D, Gan J . Pyroptosis, a new bridge to tumor immunity. Cancer Sci. 2021; 112(10):3979-3994. PMC: 8486185. DOI: 10.1111/cas.15059. View

Niu X, Chen L, Li Y, Hu Z, He F . Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC. Semin Cancer Biol. 2022; 86(Pt 3):273-285. DOI: 10.1016/j.semcancer.2022.03.009. View

Jin H, Xie W, He M, Li H, Xiao W, Li Y . Pyroptosis and Sarcopenia: Frontier Perspective of Disease Mechanism. Cells. 2022; 11(7). PMC: 8998102. DOI: 10.3390/cells11071078. View

Li L, Song D, Qi L, Jiang M, Wu Y, Gan J . Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis. Cancer Lett. 2021; 520:143-159. DOI: 10.1016/j.canlet.2021.07.014. View

Du T, Gao J, Li P, Wang Y, Qi Q, Liu X . Pyroptosis, metabolism, and tumor immune microenvironment. Clin Transl Med. 2021; 11(8):e492. PMC: 8329701. DOI: 10.1002/ctm2.492. View

Gajewski T, Schreiber H, Fu Y . Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14(10):1014-22. PMC: 4118725. DOI: 10.1038/ni.2703. View

10.

Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J . The role of pyroptosis in cancer: pro-cancer or pro-"host"?. Cell Death Dis. 2019; 10(9):650. PMC: 6733901. DOI: 10.1038/s41419-019-1883-8. View

11.

Guo K, Zhuo Z, Chen P, Wu H, Yang Q, Li J . Construction of a pyroptosis-related classifier for risk prediction of acute myocardial infarction. Rev Cardiovasc Med. 2022; 23(2):52. DOI: 10.31083/j.rcm2302052. View

12.

Huang Y, Wang J, Huang J, Tang L, Xu Y, Sun H . Pyroptosis, a target for cancer treatment?. Apoptosis. 2022; 27(1-2):1-13. DOI: 10.1007/s10495-021-01703-y. View

13.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

14.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

15.

Smyth E, Lagergren J, Fitzgerald R, Lordick F, Shah M, Lagergren P . Oesophageal cancer. Nat Rev Dis Primers. 2017; 3:17048. PMC: 6168059. DOI: 10.1038/nrdp.2017.48. View

16.

Jiang M, Wu Y, Qi L, Li L, Song D, Gan J . Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma. Chem Biol Interact. 2021; 350:109704. DOI: 10.1016/j.cbi.2021.109704. View

17.

Al Mamun A, Suchi S, Aziz M, Zaeem M, Munir F, Wu Y . Pyroptosis in acute pancreatitis and its therapeutic regulation. Apoptosis. 2022; 27(7-8):465-481. DOI: 10.1007/s10495-022-01729-w. View

18.

Wu M, Wang Y, Yang D, Gong Y, Rao F, Liu R . A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma. EBioMedicine. 2019; 41:244-255. PMC: 6442225. DOI: 10.1016/j.ebiom.2019.02.012. View

19.

Hirano H, Kato K . Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol. 2019; 49(5):412-420. DOI: 10.1093/jjco/hyz034. View

20.

Abnet C, Arnold M, Wei W . Epidemiology of Esophageal Squamous Cell Carcinoma. Gastroenterology. 2017; 154(2):360-373. PMC: 5836473. DOI: 10.1053/j.gastro.2017.08.023. View